KRYS Krystal Biotech, Inc.
$320.58▲ +2.21%
Healthcare
Other
Volume 212.8K
Avg Volume (10D) 268.3K
Key Metrics & Fundamentals
Market Cap
$9.49B
P/E Ratio
40.2
Div Yield
0.00%
52W Range
183.26 - 382.54
% vs 50 MA
-5.20%
% vs 200 MA
4.11%
RSI-14
45.1
MACD Histogram
-0.4100
Beta (1Y vs SPY)
0.70
Free Cash Flow
$71.22M
Gross Rev
$119.22M
Gross Profit
$112.79M
EBITDA
$59.98M
COGS
$6.44M
Operating Exp
$54.37M
Operating Income
$58.42M
EBIT
$58.42M
Pretax Income
$66.08M
Net Income
$54.77M
EPS (Diluted)
1.79
Price & Volume History
Loading chart…
Recent News
Has The Story Under Krystal Biotech Stock Run Out?
Trefis · Oct 28, 2026 4:22 AM ET
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Zacks · Oct 27, 2026 9:00 AM ET
Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
Zacks · Oct 26, 2026 9:00 AM ET
Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
PR Newswire · Oct 21, 2026 10:31 AM ET
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Zacks · Oct 16, 2026 10:19 AM ET
Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin
InvestorsHub · Oct 15, 2026 10:06 AM ET
Krystal Biotech Says KB113 Demonstrates Significant Regression in Lesions in Gorlin Syndrome Pilot Study
MT Newswires · Oct 15, 2026 7:40 AM ET
Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
GlobeNewswire · Oct 15, 2026 7:00 AM ET
What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders
Simply Wall St. · Oct 8, 2026 12:12 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See KRYS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.